Patient Care
Access to Medicine
Our Commitment
Recordati has always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege. Whether that is for common diseases or the rarest, we want to give all people the opportunity to be the best version of themselves by having access to affordable, innovative and sustainable healthcare.
Some of the ways in which we promote access are:
FOCUSED ON THE FEW
We care for the most vulnerable patients through the Rare Disease Division and through specific Patient Access Programmes. During 2024, we supported more than 1,600 rare disease patients with Patient Assistance Program (PAP), Co-Pay Assistance Program (CAP) and similar programmes.*
*These two programs are active in the USA and Canada and are focused on Endocrinology, Oncology, and Metabolic therapeutic areas. Similar programs are in place in other geographic areas, for instance, China, Colombia and Argentina.
INNOVATIVE MEDICINE
Recordati is committed to advancing medical treatments for both existing and emerging markets. With a specific focus on rare diseases, Recordati actively engages in the development of new medicines both internally and through agreements with other pharmaceutical companies and research institutes.
SUPPORTING PATIENT ASSOCIATIONS, CAREGIVERS, DOCTORS AND INSTITUTIONS
Our goal is to increase awareness, promote improved diagnosis, and expand the availability of treatments, especially for people with rare diseases.
ACCESS TO QUALITY CARE
Through Specialty & Primary Care, we provide high-quality and affordable products for a broad range of therapeutic areas, also in low- and middle-income countries. Additionally, we introduced in 2024 the “Health Caravans” project in Tunisia to reduce health inequality and provide equal access to treatments.
PRODUCT DONATIONS
We provide medicines to disadvantaged people who are unable to purchase them or find themselves in humanitarian emergencies.
Health Caravans Project in Tunisia
Access to healthcare remains a challenge in Tunisia, especially in rural areas. This project aims to provide access to specialist medical treatment in the most disadvantaged rural areas of the country. The initiative involved a team of cardiologists, who conducted over 350 patient visits.
The health caravans are a further iteration of our commitment to reduce health inequality and provide equal access to treatments, with the goal of promoting wellbeing and improving quality of life for vulnerable communities.
Patient Care
Our Approach Towards Patients
“We are making progress in moving our R&D pipeline forward, all to support the overall mission of the Recordati Group, and driving meaningful innovation that truly improves patients’ lives.”
Milan Zdravkovic
Executive Vice President, R&D
Patient Care
Empowering Lives
Enhancing Patient Care and Education in Specialty & Primary Care (SPC)
At Recordati SPC, we are committed to empowering patients with the knowledge and support they need to navigate their diagnosis and maximise the benefits of their treatments, while promoting overall well-being.
SPC's 2024 Patient Support Initiatives
Go Beyond
A prostate cancer diagnosis can leave many men feeling uncertain, lost, and even disconnected from their sense of self. The journey beyond diagnosis is often filled with questions – what comes next, and how can life be truly lived beyond the disease?
GO BEYOND is the heart of SPC’s Patient Support Initiatives – a commitment from Recordati to stand by men as they navigate this new chapter, providing robust resources containing the knowledge, tools, and guidance needed to help men regain confidence, purpose, and a renewed sense of identity.
With practical strategies, SPC strives to offer comprehensive physical and psychological support—equipping men with the skills to take control, rebuild their strength, and embrace life beyond cancer.
The Candid Book
The Candid Book helps families of people living with schizophrenia to shape their role as a caregiver, solving dilemmas and answering questions. Written by experts in the field, the authors speak directly to everyone affected by schizophrenia, regardless of the role they play.
Anti Cyberbullying Campaign
In an era when digital technologies constitute an increasing part of young people’s daily lives, cyberbullying is not just a social issue but a real threat to mental health and well-being, affecting up to 30% of students in Italy, with hundreds of cases reported to the police each year.
With its core message “Feel the Care”, Alovex®— Recordati’s leading brand for mouth ulcer treatment—extended its commitment to protection and wellbeing beyond physical discomfort. Recognizing that cyberbullying, much like mouth ulcers, causes pain and distress that often goes unnoticed, the brand took action to support teenagers facing this issue.
The initiative led to a 70% increase in requests for help to the Bulli Stop Association, with a growing number of schools eager to promote awareness, plus remarkable digital engagement metrics.
Patient Care
Focused on the Few
Rare Diseases: Our Commitment to the Patient Community
We focus on the few, those affected by rare diseases, and we believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions. For us, patient centricity represents a partnership with the patient community, ensuring that their voices are integral to creating effective, patient-aligned healthcare solutions.
Our approach towards patients is evident in the projects we initiated during 2024: the creation of a Patient Ambassador Group and the development of the Patient Community Charter together with our patient community.
Patient Ambassador Group
Our Patient Ambassadors at Rare Diseases serve as the voice of the patient community within their affiliate or areas of business.
Patient Community Charter
Our Patient Community Charter* underscores our unwavering commitment to embedding the voices and needs of patients with rare diseases into every aspect of our work. This Charter aspires to position Rare Diseases as a trusted partner within the rare disease community, ensuring that patient input meaningfully shapes our actions, decisions, and outcomes.
*Intended audience: International, excluding the US
Raising Awareness of Rare Diseases: 2024 Initiatives
Collaboration with the Castleman Disease Collaborative Network
Our commitment to raising awareness and improving outcomes for patients with idiopathic multicentric Castleman disease (iMCD) remained a central focus of the disease awareness initiatives promoted in 2024. Through a strong collaboration with the Castleman Disease Collaborative Network (CDCN), we supported three key events: the Quest for a Cure, the Patient & Loved One Summit, and the Physician & Researcher Annual Meeting at ASH. These events provided vital platforms for education, connection, and collaboration among patients, caregivers, and medical professionals.
2024 Edition of the International Prize for Scientific Research Arrigo Recordati
At the 5th Annual Meeting of the European Society for Paediatric Oncology (SIOP) in Milan, the 11th edition of the International Prize for Scientific Research Arrigo Recordati was awarded to Dr. Adam Durbin from St. Jude Children’s Research Hospital in Memphis. Dr. Durbin was recognized for his groundbreaking work in developing new potential therapeutic strategies for children with neuroblastoma.
Established in 2000 in memory of the esteemed Italian pharmaceutical entrepreneur Arrigo Recordati, the Prize aims to perpetuate his legacy and inspire biomedical discoveries that benefit people worldwide. The 2024 edition, open to young researchers of any nationality, focused on promoting and recognizing excellence in paediatric oncology research, specifically targeting neuroblastoma.
Dr. Durbin’s project was selected from over 40 entries by an independent panel of internationally recognized rare disease experts and was awarded a €100,000 research grant.
Recordati Rare Diseases Fondation d’Entreprise
The Recordati Rare Diseases Foundation was established to provide independent and unconditional support for training programmes aimed at the scientific community in the field of rare diseases. The overall objective is to share experience in the diagnosis, management and outcome of rare disorders, giving specialists the opportunity to broaden their expertise, develop new ideas and establish scientific relationships.
In 2024, three live medical education courses were organised in Endocrinology and Inborn Errors of Metabolism, confirming the role of the Foundation as a key player in medical education in these fields.
Q Bag for Children Undergoing High Risk Neuroblastoma Treatment
Our partnership with the Dutch Childhood Cancer Association (VKKN) and the patient community at the Princess Maxima Paediatric Oncology Center is a great real-word example of a collaborative effort to improve care for young patients.
It began informally with children and families sharing their experiences with continuous IV immunotherapy for high-risk neuroblastoma (HRNB), highlighting the restrictions of traditional infusion pumps which are normally attached to an IV-pole or carried in a shoulder bag.
Inspired by a parent, our Rare Diseases team in the Netherlands, along with the Princess Maxima Hospital and a design agency, developed the Q-bag, a safe and robust backpack for IV pumps. Continuous feedback from children and families throughout the development process have contributed to the user-friendly and appealing design of Q-bag. Now, all children with HRNB in the Netherlands receive a Q-bag, featuring bespoke safety and personalized design options.
Our team’s work was also internationally recognized as a best practice in partnerships, achieving “Gold Standard” at the 2024 Patient Partnership Index (PPI). The PPI recognises and evaluates collaborative projects between the pharmaceutical industry and patient groups, providing an excellent opportunity for reflection and feedback on patient partnership.
Discover More about our commitment to patients
For more information, please refer to the Consolidated Sustainability Statement.